Resmed beats quarterly profit estimates on strong demand for sleep devices

Resmed (RMD.N) surpassed Wall Street's fourth-quarter profit and revenue estimates, driven by robust demand for its sleep apnea devices. The company reported a 10% revenue increase to $1.35 billion and adjusted earnings of $2.55 per share, exceeding analyst expectations of $1.33 billion and $2.48 per share, respectively. Resmed also dismissed concerns regarding Eli Lilly's Zepbound impacting demand, suggesting that consumer wearables and GLP-1 therapies could instead encourage greater utilization of its devices.

Analysis

ResMed (RMD) delivered a strong fourth-quarter performance, exceeding Wall Street expectations on both revenue and profit. The company reported a 10% year-over-year revenue increase to $1.35 billion, surpassing the consensus estimate of $1.33 billion, driven by sustained demand for its sleep apnea devices. Adjusted earnings per share came in at $2.55, beating the anticipated $2.48. A key element of the report is management's direct rebuttal of concerns that GLP-1 drugs, such as Eli Lilly's Zepbound, will erode its market. ResMed's leadership posits a counter-narrative, suggesting that increased health awareness from GLP-1 therapies and consumer wearables will actually expand the pool of diagnosed sleep apnea patients, ultimately driving more users toward its device-based treatments.

Key Decisions for Investors

• The earnings and revenue beat indicates solid near-term operational execution and resilient demand, which may support a bullish stance for investors focused on current fundamentals.
• The primary long-term risk factor to monitor is the adoption rate of GLP-1 drugs like Zepbound for sleep apnea; investors should scrutinize future sales data to validate or challenge management's synergy thesis.
• It is crucial to assess future company reports for tangible evidence that increased patient awareness from GLP-1s is translating into higher device sales, as this will be the key determinant of the long-term growth narrative.